ADCOCK INGRAM HOLDINGS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.06 ZAR | -1.34% |
|
+0.11% | -8.39% |
| 21/02 | Adcock Ingram Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| 21/02 | Transcript : Adcock Ingram Holdings Limited, H1 2024 Earnings Call, Feb 21, 2024 |
ETFs positioned on Adcock Ingram Holdings Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +4.82% | - | |
| 0.00% | 34 M€ | +4.35% | - |
Adcock Ingram Holdings Limited is one of South Africa's largest pharmaceutical groups. The group also provides hospital products. Net sales break down by family of products as follows:
- pharmaceutical products (79.2%): OTC medicines, prescription products, etc.;
- hospital products (20.8%; No. 1 in South Africa).
At the end of June 2023, the group had 3 production sites located in South Africa.
France accounts for 98.6% of net sales.
Sector
Pharmaceuticals
Calendar
21/08/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
55.06
ZAR
Average target price
56
ZAR
Spread / Average Target
+1.71%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.39% | 43Cr | |
| +16.93% | 4.28TCr | |
| +22.20% | 2.28TCr | |
| +16.96% | 1.5TCr | |
| +18.51% | 1.45TCr | |
| +51.63% | 1.27TCr | |
| -0.05% | 678.76Cr | |
| -11.45% | 673.57Cr | |
| -8.87% | 572.55Cr | |
| +14.55% | 547.45Cr |
- Stock Market
- Equities
- AIP Stock
- Funds and ETFs Adcock Ingram Holdings Limited
